DexCom, Inc. reported “lighter than usual results” during the fourth quarter dealing with COVID-related headwinds, but Wells Fargo analyst Larry Biegelsen remains upbeat that the upcoming launch of the next-generation G7 continuous glucose monitoring device could turn out to be a major catalyst for the San Diego, CA-based CGM maker.
On 10 January, Dexcom reported preliminary fourth-quarter revenue of about $698m, which were in line with Dexcom’s guidance and...






